Ftse Mib
34.603,61
-0,64%
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
NASDAQ
16.832,62
0,22%
Bitcoin
70.179,61
-1,78%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ REGENXBIO Inc (RGNX) REGENXBIO Inc (RGNX) Notizie

RGNX

REGENXBIO (RGNX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RGNX
DataOraFonteTitoloSimboloCompagnia
16/05/202423:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGNXREGENXBIO Inc
14/05/202422:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RGNXREGENXBIO Inc
10/05/202413:05PR Newswire (US)REGENXBIO to Participate in Upcoming Investor ConferencesNASDAQ:RGNXREGENXBIO Inc
08/05/202422:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGNXREGENXBIO Inc
08/05/202422:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGNXREGENXBIO Inc
08/05/202422:05PR Newswire (US)REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
01/05/202413:05PR Newswire (US)REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
24/04/202413:05PR Newswire (US)REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitNASDAQ:RGNXREGENXBIO Inc
28/03/202412:05PR Newswire (US)REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDNASDAQ:RGNXREGENXBIO Inc
27/03/202421:05PR Newswire (US)REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy DaysNASDAQ:RGNXREGENXBIO Inc
08/03/202412:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RGNXREGENXBIO Inc
07/03/202412:03Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:RGNXREGENXBIO Inc
07/03/202405:20PR Newswire (US)REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded WarrantsNASDAQ:RGNXREGENXBIO Inc
06/03/202422:10PR Newswire (US)REGENXBIO Announces Proposed Public Offering of Common StockNASDAQ:RGNXREGENXBIO Inc
05/03/202413:05PR Newswire (US)REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIALNASDAQ:RGNXREGENXBIO Inc
29/02/202422:57PR Newswire (US)REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
27/02/202422:54Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGNXREGENXBIO Inc
27/02/202422:05PR Newswire (US)REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
21/02/202413:05PR Newswire (US)REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
07/02/202417:40PR Newswire (US)REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary EndpointNASDAQ:RGNXREGENXBIO Inc
07/02/202413:05PR Newswire (US)REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
31/01/202413:05PR Newswire (US)REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024NASDAQ:RGNXREGENXBIO Inc
16/01/202420:47PR Newswire (US)REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal DeliveryNASDAQ:RGNXREGENXBIO Inc
10/01/202413:05PR Newswire (US)REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 MeetingNASDAQ:RGNXREGENXBIO Inc
08/01/202413:05PR Newswire (US)U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement LawsuitNASDAQ:RGNXREGENXBIO Inc
29/11/202313:05PR Newswire (US)REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
08/11/202322:05PR Newswire (US)REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial ResultsNASDAQ:RGNXREGENXBIO Inc
03/11/202323:53PR Newswire (US)REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal DeliveryNASDAQ:RGNXREGENXBIO Inc
01/11/202312:05PR Newswire (US)REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
30/10/202312:05PR Newswire (US)REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual MeetingNASDAQ:RGNXREGENXBIO Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RGNX

La tua Cronologia

NYSE
EQ
Embarq
LSE
106K
LSE
ASW
Advanced Computer Software
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network